IL2 and metabolic dysfunction-associated steatotic liver disease: Thus, IL-2 may also act as a dual-faceted molecule; we could hypothesize that IL-2 aims to ameliorate MASLD in the early stages, but when this mechanism fails and IL-2 concentrations are further increased, it may contribute to the progression of MASLD; however, this hypothesis remain to be shown.